Alternatives to risankizumab
1 same-class SPL records vs risankizumab - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Skyrizi
About risankizumab
Skyrizi is a medicine that can help reduce inflammation in your body. It is used to treat conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Used for: Skyrizi is used to treat moderate to severe plaque psoriasis in adults. It can help reduce the red, scaly patches on your skin. Skyrizi also treats active psoriatic arthritis, which causes joint pain and swelling. Skyrizi can also treat moderately to severely active Crohn's disease and ulcerative colitis, which are inflammatory bowel diseases.
1 Anti-IL-23 Monoclonal Antibody peers (wide set)
risankizumab peer mix vs class inventory
Peer mix
0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Anti-IL-23 Monoclonal Antibody: 2 drugs.
Frequently Asked Questions
What same-class SPL records sit beside risankizumab? ▼
Reading a wide Anti-IL-23 Monoclonal Antibody peer set (1 records)
risankizumab (Skyrizi) sits in a wide Anti-IL-23 Monoclonal Antibody peer set (1 of 1 class peers shown). Labeled indication field for risankizumab: Skyrizi is used to treat moderate to severe plaque psoriasis in adults.
FAERS top-reaction fields are thin or absent for risankizumab in this extract; peer cards still expose SPL indication and OTC/Rx flags.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for risankizumab: see also the generic vs brand label guide when reading Skyrizi SPL strings.
Read our methodology - how this data is sourced, computed, and verified.